Quince Therapeutics regains Nasdaq bid price compliance; still faces MVLS deficiency

Quince Therapeutics, Inc.

Regained compliance with Nasdaq minimum bid price rule (closing bid >= $1.00 for 10 consecutive business days through April 24, 2026).
Still not compliant with Nasdaq market value of listed securities (MVLS) requirement (must be at least $50M); compliance period ends September 14, 2026.
No assurance given that company will meet MVLS requirement or maintain other listing standards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.